NasdaqGS:REGNBiotechs
Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?
Earlier this week, Regeneron Pharmaceuticals announced that the FDA approved Pasatru (garetosmab-grts), a monthly intravenous monoclonal antibody, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with the ultra-rare disease fibrodysplasia ossificans progressiva.
The approval is based on Phase 3 OPTIMA trial data showing Pasatru cut new abnormal bone lesions to just a few cases compared with many more on placebo, while also enabling administration...